Lu AE04621

❧

Wikipedia

Lu AE04621
Clinical data
Other namesLu-AE04621; Lu AE 04621; LuAE04621
Routes of
administration		Oral[1]
Drug classDopamine receptor agonist; Dopamine D1 and D2 receptor agonist
ATC code
  • None

Lu AE04621 is a dopamine receptor agonist which is or was under development for the treatment of Parkinson's disease but has not been marketed.[1][2][3] It is taken orally.[1] The drug is said to be a prodrug of the catecholamine Lu AA40326 and to act as a dual dopamine D1 and D2 receptor agonist.[1][2][3][4] Lu AE04621 is or was under development by Lundbeck.[1][2] As of November 2023, it is in phase 1 clinical trials and has been since at least 2016, but no recent development has been reported since February 2019.[1] The chemical structure of Lu AE04621 has not yet been disclosed.[1][2][3] However, it may be a prodrug of 5,6-diOH-DPAT or a related approach.[2]

See also

References

  1. 1 2 3 4 5 6 7 "Lu AE 04621". AdisInsight. 5 November 2023. Retrieved 28 January 2026.
  2. 1 2 3 4 5 Ellis JM, Fell MJ (September 2017). "Current approaches to the treatment of Parkinson's Disease". Bioorganic & Medicinal Chemistry Letters. 27 (18): 4247–4255. doi:10.1016/j.bmcl.2017.07.075. PMID 28869077.
  3. 1 2 3 Mao Q, Qin WZ, Zhang A, Ye N (April 2020). "Recent advances in dopaminergic strategies for the treatment of Parkinson's disease". Acta Pharmacologica Sinica. 41 (4): 471–482. doi:10.1038/s41401-020-0365-y. PMC 7471472. PMID 32112042.
  4. ↑ Clinical trial number NCT02649608 for "An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients" at ClinicalTrials.gov